Gokul Das, PhD

Associate Professor
Department of Pharmacology and Therapeutics
Center for Genetics and Pharmacology Building
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263, USA

Associate Professor
Department of Pharmacology and Therapeutics
Center for Genetics and Pharmacology Building
Roswell Park Cancer Institute
Elm and Carlton Streets
Buffalo, NY 14263, USA


Dr. Das is Associate Professor and Co‐Director of Breast Disease Site Research Group at Roswell Park Cancer Institute, Buffalo, New York. Dr. Das obtained Ph.D. from Baylor College of Medicine, Houston, Texas, followed by Postdoctoral research at the Cold Spring Harbor Laboratory, Long Island, New York. For the past twelve years, he has been a faculty member at the Roswell Park Cancer Institute, an NCI- designated Comprehensive Cancer Center. Dr. Das has extensive experience in cancer (especially breast cancer) in both basic and translational research arenas. He has gained experience in conducting both retrospective and prospective clinical studies. His laboratory uses cell culture and animal models along with patient tissues to investigate cellular and molecular mechanisms underlying the onset and progression of cancer and translating them to the clinic when possible. He is a principal investigator on the prospective clinical trial (originally funded by NCI) on the effect of estrogen receptor-p53 interaction on tamoxifen therapy in breast cancer patients.

Research Interest

His research interests include: Estrogen receptor and tumor suppressor protein P53 signaling in breast and lung cancers.

Scientific Activities


•(2004) Whos Who in Medicine and Healthcare
•(1988) Mead Johnson Research Excellence Award: 19th Annual National Student Research Forum (USA)
•(1979) First position, Graduate Proficiency Test, Jawaharlal Nehru University, New Delhi, India
•(1976) Outstanding Teacher of Science (during B.Ed. program)


•(2013-Present) Member, Special Emphasis Panel, NCI omnibus R21/R03 FOA
•(2004, 2011-Present) Member, Grant review Panel, Roswell Park Alliance Foundation
•(2013) Member, Special Emphasis Panel on “Fellowship: Oncological Sciences”, NIH
•(2011-2012) Member, NIH Cancer Etiology (CE) Study Section
•(2011) Chair, Institutional Alliance Foundation Breast Cancer Grant Review Panel
•(2009) Member, NIH Challenge Grant Review Panel
•(2005-2010) Member, General Biomedical Science study section, Tobacco-Related Disease Research Program (TRDRP), University of California
•(2004-2010) Member, Grant Review Panel, DOD Breast Cancer Research Program


1. Wickramesekera NT, Das GM. Tumor suppressor p53 and estrogen receptors in nuclear-mitochondrial communication. Mitochondrion. 2013; 16: 26-37. doi: 10.1016/j.mito.2013.10.002.
2. Tang L, Ling X, Liu W, Das GM, Li F. Transcriptional inhibition of p21WAF1/CIP1 gene (CDKN1) expression by surviving is at least partially 53-dependent: Evidence for surviving acting as a transcription factor or co-factor. Biochem Biophys Res Commun. 2012; 421: 249-254.
3. Nayvelt I, John S, Hsu HC, et al. A potential estrogen mimetic effect of a bis(ethyl)polyamine analogue on estrogen receptor positive MCF-7 breast cancer cells. Amino Acids. 2012; 42: 899-911. doi: 10.1007/s00726-011-1005-0.
4. Liu W, Swetzig WM, Medisetty R, Das GM. Estrogen-mediated upreulation of noxa is associated with cell cycle progression in estrogen-receptor-positive breast cancer cells. PLoS One. 2011; 6(12): e29466. doi: 10.1371/journal.pone.0029466
5. Konduri S, Medisetty R, Liu W, et al. Mechanisms of Estrogen receptor antagonism towards p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc Natl Acad Sci USA. 2010; 107: 15081-15086. doi: 10.1073/pnas.1009575107.
6. Liu W, Ip MM, Podgorsak MB, Das GM. Disruption of estrogen receptor α-p53 interaction in breast tumors: A novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Research and Treatment. 2009; 115: 43-50. doi: 10.1007/s10549-008-0044-z.
7. John S, Nayvelt I, Hsu H-C, et al. Regulation of estrogenic effects by beclin 1 in breast cancer cells. Cancer Research. 2008; 68: 7855-7863. doi: 10.1158/0008-5472.CAN-07-5875.
8. Karipparettu BA, Zubairy S, Konduri SD, et al. Estrogen-mediated down-regulation of CD24 in breast cancer cells. International Journal of Cancer. 2008; 123: 66-72. doi: 10.1002/ijc.23480.
9. Sayeed A, Konduri S, Liu W, Bansal S, Li F, Das GM. Estrogen receptor α inhibits p53-mediated transcriptional repression: Implications for the regulation of apoptosis. Cancer Research. 2007; 67: 7746-7755. doi: 10.1158/0008-5472.CAN-06-3724
10. Liu W, Konduri S, Bansal S, et al. Estrogen receptor-alpha binds p53 tumor suppressor protein directly and represses its function. J Biol Chem. 2006; 281: 9837-9840. doi: 10.1074/jbc.C600001200
11. Desouki MM, Kulawiec M, Bansal S, Das G, Sing KK. Cross talk between mitochondria and superoxide generating NADPH oxidase in breast and ovarian tumors. Cancer Biology & Therapy. 2005; 4: 1367-1373. doi: 10.4161/cbt.4.12.2233
12. Narayan S, Jaiswal AS, Kang D, Srivastava P, Das G, Gairola CG. Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro.Oncogene. 2004; 23: 5880-5889. doi: 10.1038/sj.onc.1207792
13. Nayak B, Das G. Stabilization of p53 and transactivation of its target genes in response to replication blockade. Oncogene. 2002; 21: 7226-7229. doi: 10.1038/sj.onc.1205889
14. Giabernardi TA, Sakaguchi AY, Gluhak J, et al. Neutrophil collagenase (MMP-8) is expressed during early development in neural crest cells as well as in adult melanoma cells. Matrix Biology. 2001; 20: 577-587. doi: 10.1016/S0945-053X(01)00166-4
15. Thavathiru E, Das G. Activation of pRL-TK by 12S E1A oncoprotein: drawbacks of using an internal reference reporter in transcription assays. BioTechniques. 2001; 31: 528-532.
16. Karuppayil S, Moran E, Das G. Differential regulation of p53-dependent and -independent PCNA transcription by adenoviral 12S E1A oncoprotein. J Biol Chem. 1998; 273: 17303-17306. doi: 10.1074/jbc.273.28.17303
17. Das G, Hinkley CS, Herr W. Basal promoter elements as a selective determinant of transcriptional activator function. Nature. 1995; 374: 657-660. doi: 10.1038/374657a0
18. Rajasekharan AK, Zhou Z, Prakash K, Das G, Kreibich G. Functional characterization of the cis-regulatory elements of the rat ribophorin gene. Nucl Acid Res. 1995; 23: 313-319. doi: 10.1093/nar/23.3.313
19. Das G, Herr W. Enhanced activation of the human histone H2B promoter by the Oct-1 variant generated by alternative splicing. J Biol Chem. 1993; 268: 25026-25032.
20. Sturm RA, Cassady JL, Das G, Romo A, Evans GA. Chromosomal structure and expression of the human OTF1 locus encoding the Oct-1 protein. Genomics. 1993; 16: 333-341. doi: 10.1006/geno.1993.1194
21. Sturm R, Das G, Herr W. The ubiquitous octamer-binding protein Oct-1 contains a POU domain with a homeo box subdomain. Genes & Dev. 1988; 2: 1582-1599. doi: 10.1101/gad.2.12a.1582
22. Das G, Henning D, Wright D, Reddy R. Upstream regulatory elements are necessary and sufficient for transcription of a U6 gene by RNA polymerase III. EMBO J. 1988; 7: 503-512.
23. Das G, Henning D, Reddy R. Structure, organization and transcription of Drosophila U6 small nuclear RNA genes. J Biol Chem. 1987; 262: 1187-1193.
24. Reddy R, Henning D, Das G, Harless M, Wright D. The capped U6 small nuclear RNA is transcribed by RNA polymerase III. J Biol Chem. 1987; 262: 75-81.
25. Das G, Henning D, Reddy R. One aspartic acid transfer RNA gene is present upstream of the U6 RNA gene cluster in Drosophila melanogaster. Nucl Acid Res. 1986; 14: 7816.
26. Rao AR, Das G, Das P. Inhibitory action of aminoglutethemide on DMBA induced mammary carcinogenesis. Oncology. 1985; 42: 119-121.